Interleukin (IL)-6-type cytokines such as IL-6, oncostatin M (OSM) and leukaemia inhibitory factor (LIF) signal through receptor complexes that are critically dependent on gp130. The latter is the common signal-transducing molecule that couples these cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). IL-6-type cytokine signalling additionally involves the recruitment and activation of extracellular signal-regulated kinase (ERK) 1 and ERK2. Both STATs and ERKs regulate responses mediated by members of the IL-6 family. Here, we show that ERK2, but not ERK1, also controls the expression and function of gp130 per se, as silencing ERK2 in human osteosarcoma U2OS cells inhibits the expression of gp130. This does not simply reflect quantitative differences between ERK1 and ERK2, and the effects are not restricted to osteosarcoma cells, as they can be extended to several other cancer cell types analysed to date (such as breast, prostate, lung and cervical cancer cells). Importantly, ERK2 binds to the GP130 promoter, where it perhaps interacts with the transcriptional machinery. Indeed, its role in the transcriptional regulation of the GP130 gene was corroborated using luciferase reporter assays and messenger RNA stability experiments. Considering the pivotal role that gp130 has in cancer and inflammation these data thus identify novel non-overlapping functions for ERK1 and ERK2 that are biologically relevant.
INTRODUCTION
One fifth of all cancers are thought to be associated with chronic inflammation. 1 Inflammatory cytokines such as interleukin (IL)-6 are frequently elevated in cancer patients and this correlates with adverse prognosis. [1] [2] [3] Karin and co-workers have demonstrated that IL-6 can be a tumour promoting cytokine by virtue of causing inflammation and STAT3 activation. 4 STAT3 is recognised as a bona fide oncogene 5 and constitutive tyrosine phosphorylation of STAT3 on position 705 (Y705), which is indicative of activation, is observed in a surprisingly large number of tumours. 6, 7 Though abnormally activated in so many cancer cells, STAT3 mutations are not very common, with perhaps the exception of large granular lymphocytic leukaemia, 8 arguing that deregulated signalling upstream of STAT3 is an important component of carcinogenesis. Interestingly, IL-6-type cytokine signalling can trans-activate the epidermal growth factor receptor (EGFR), thereby enhancing tumour growth, 9 and STAT3 without classical activation can transform cells through novel/non-canonical mechanisms. [10] [11] [12] STAT3 is the main transcription factor activated by IL-6-type cytokines. [13] [14] [15] [16] These cytokines (for example, IL-6, oncostatin M (OSM), leukaemia inhibitory factor (LIF)) not only activate Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signalling but also trigger phosphorylation of extracellularregulated kinase (ERK) 1 and ERK2. Both arms of the response have an impact on biological responses triggered by IL-6-type cytokines. 14, [17] [18] [19] These cytokines signal through diverse receptor complexes that have in common a subunit called gp130 and a variable subunit (IL-6R, OSMR, LIFR). The gp130 has several intracellular tyrosine residues that become phosphorylated by three distinct JAKs upon ligand binding, thus creating docking sites for the STATs. STATs can also be recruited via OSMR and LIFR. Additional tyrosine residues on gp130, LIFR or OSMR recruit SRC homology (SH) 2 domain-containing tyrosine phosphatase 2 (SHP2/PTPN11) or SH2 domain containing (SHC) transforming protein, and the suppressor of cytokine signalling (SOCS) 3. 14, 18 SHP2 and SHC can trigger mitogen-activated protein kinase (MAPK) signalling downstream of IL-6/LIF and OSM, respectively. [20] [21] [22] Increased secretion of IL-6-type cytokines can lead to deregulated activation of IL-6 signalling, 23 and gain-of-function mutations within the GP130 gene can lead to an increase of its cellular functions and constitutive STAT3 activation. 24 IL-6 induces many antiapoptotic genes through activation of STAT3 and MAPKs, thereby contributing to cancer cell survival and cancer progression. 25, 26 In addition, IL-6-type cytokines have critical roles in embryonic cell development. 3, 26 These properties, and more recently recognised roles in inflammation-associated cancers, explain why a considerable amount of effort is going into developing therapies that target gp130, STAT3 and MAPK signalling in the clinic. Much is known about JAK/STAT and MAPK signalling downstream of IL-6-type cytokines, but how all the molecules involved in these signalling pathways interact and are potentially regulated by each other remains to be fully understood, and was the main aim of our study.
The MAPKs ERK1 and ERK2 are highly homologous serine/ threonine kinases, ubiquitously expressed and can be activated by 1 the same upstream effectors. They also share many substrates and are often assumed to have identical cellular roles, which depend on their relative expression. 27 Indeed, Lenormand and co-workers provided striking evidence for the indiscriminate activation of the two kinases by the same effectors and a direct correlation between the activation and expression levels of ERK1 and ERK2. The fact that Erk2 À / À mice are embryonic lethal 28 and Erk1
À / À viable 29 has also been attributed to generally lower Erk1 levels seen in most cells. More recent work, however, has provided evidence for the existence of additional, distinct, cellular functions. For example, keratinocytes from Erk1 À / À mice proliferated less in response to mitogenic factors, displayed impairment in c-Fos expression and were more resistant to the development of skin papillomas than the wild-type cells. 30 It is also clear that ERKs have additional functions that do not depend on their kinase activity and that they can bind to specific DNA sequences. 31 Despite reports that ERK1 opposed some of ERK2 mitogenic functions, a recent study by Meloche and co-workers, employing both mouse embryonic fibroblasts (MEFs) and RNAi, strongly argues against this. 32 A similar study has not been conducted in the context of IL-6-type cytokine signalling. We therefore investigated the impact of genetic inhibition of ERK1 or ERK2 on molecular events triggered by IL-6-type cytokines in human U2OS osteosarcoma cells. Here, we show that genetic ablation, but not chemical inhibition, of ERK2 leads to a nearly complete abrogation of gp130 expression, a receptor essential to transduce IL-6-type cytokine signals. ERK2 has an impact on GP130 transcription. It binds to the GP130 promoter and may thus regulate this protein's expression by interacting with the mediator complex or by remodelling the chromatin. Luciferase-based reporter assays and experiments involving the transcription inhibitor actinomycin D, however, argue for the former. These selective ERK2 effects are likely to have far-reaching implications, as they were observed in several other types of cancer cells, and ERK2 and gp130 protein expression were almost directly proportional.
RESULTS

Downregulation of ERK2
, but not ERK1, abrogates STAT1 and STAT3 phosphorylation in response to IL-6-type cytokines U2OS cells are highly transfectable and amenable to RNAi, which was important to study the impact that reducing the levels of ERK1 or ERK2 had on events triggered by IL-6-type cytokines. U2OS cells were treated with IL-6/sIL-6R, OSM or LIF, and time-and dose-responses carried out using STAT and ERK phosphorylation as readouts (Figure 1a and data not shown). STAT3 phosphorylation on Y705 was stronger than STAT1 phosphorylation on Y701, with OSM being the strongest activator of these transcription factors. ERK1 and ERK2 phosphorylation was also more pronounced downstream of OSM signalling. The predominant activation of ERK2 correlated with the higher expression level of this isoform in these cells. ERK2 phosphorylation was barely triggered by IL-6/sIL-6R and not detectable following LIF stimulation under these experimental conditions. U2OS cells were transfected with siRNA pools targeting ERK2 (hereinafter referred to as siERK2), ERK1 (siERK1) or with nontargeting siRNA (siNS) (Supplementary Table SI) . Forty-eight hours later whole-cell extracts were analysed by western blotting for the activation of relevant signalling components (Figure 1b) . In all experiments, untransfected cells were included in the analyses. Surprisingly, the knockdown of ERK2 completely blunted STAT3 and STAT1 tyrosine phosphorylation on critical residues upon IL-6 or OSM treatment (Figure 1b) . This was surprising, as both proteins were still highly expressed in these cells. Cells transfected with siNS oligonucleotides behaved essentially as the untransfected controls. ERK1 knockdown did not affect the expression levels of STAT3 or STAT1 nor their phosphorylation status, which was in contrast to what was seen after silencing ERK2 (Figure 1b ).
Silencing ERK2 led to an increase in ERK1 phosphorylation, which was particularly obvious after IL-6 treatment. This was intriguing, as IL-6 is a much weaker activator of the ERKs than OSM (Figures 1a and b) . However, this phosphorylation event was not ligand-dependent, as it could also be observed in U2OS cells that were transfected with siERK2 but were not challenged with any IL-6-type cytokine (Supplementary Figure S1) , and it was not cell line specific as it was also seen in A549 lung cancer cells (data not shown). (a) Kinetics of phosphorylation/activation of STAT1, STAT3, ERK1 and ERK2 in response to IL-6/sIL-6R (400 ng/ml; 500 ng/ml), OSM (50 ng/ ml) and LIF (50 ng/ml) in human osteosarcoma U2OS cells. Western blot membranes were probed with pSTAT3 Y705 , pSTAT1 Y701 and pERK1/2 T202Y204/T185Y187 , and after stripping, re-probed with antibodies against STAT1, STAT3 and ERK1/2, respectively. b-actin was used as a loading control. (b) Cells were transfected for 48 h with 20 nM siNS, siERK1, siERK2 or left untransfected (Supplementary Table I ). Cells were then treated with IL-6/sIL-6R, or OSM for 15 min and 30 mg total protein extract analysed as above. (c) Silencing ERK2, but not ERK1, led to STAT3 mRNA downregulation. Cells were transfected as before, RNA isolated and analysed by qPCR, using HPRT as a house-keeping gene. Data shown are representative of three independent experiments that yielded identical results. Statistical analysis was done using Student's t-test (*Po0.05, **Po0.01, ***Po0.005 versus siNS-transfected control). Unt: untreated; ø: untransfected control; NS: siNS; E1: siERK1, E2: siERK2. Dotted line indicates a discontinuous gel.
The transfection of U2OS cells with siERK2 also led to a decrease in the total amounts of STAT3 (Figure 1b) . In order to establish at what level this occurred, cells were transfected as described above, RNA extracted, reverse transcribed and analysed by realtime PCR (qPCR) (Supplementary Table SII ). The decrease observed at the protein level (Figure 1b) was also observed at the messenger RNA (mRNA) level ( Figure 1c ) and appeared to be B33%.
Impact of ERK2 silencing on OSM target gene induction The inhibition of STAT3 and STAT1 tyrosine phosphorylation (Figure 1b) suggested that ERK2 silencing affected OSM-mediated STAT3 and STAT1 activation. To determine to what extent the ERKs participated in STAT-target gene induction, we analysed well-described target genes of these transcription factors. RNAi against ERK1, ERK2 and, as a control, gp130 was performed as previously, and RNA extracted from untreated and OSM-treated cells was analysed by qPCR for levels of suppressor of cytokine signalling (SOCS)-3 and early growth response protein (EGR)-1, which are downstream transcriptional targets of predominantly STAT3 and ERKs, respectively ( Figure 2 and Supplementary Table SII) .
Downregulation of ERK2 greatly affected JAK/STAT signalling downstream of the gp130/OSMR complex, as SOCS3 mRNA induction was reduced more than 2.5-fold (B60%) when compared with the levels measured in siNS-transfected cells (Figure 2a ). Silencing ERK1 actually increased 1.4-fold the induction of SOCS3 by OSM when compared with the siNStransfected cells. In control cells, direct downregulation of gp130 reduced the mRNA induction by 14-fold (B93%).
Interestingly, silencing ERK1 or ERK2 modulated EGR-1 mRNA in opposite ways: silencing ERK1 led to a 1.6-fold increased induction of EGR-1, whereas silencing ERK2 led to 1.7-fold decrease. This reflected perhaps an antagonistic role of these kinases in the regulation of this particular gene. EGR-1 mRNA levels were also reduced following RNAi against gp130 (B50% versus siNS), presumably due to the downregulation of STAT/ERK signalling in these cells, as OSM relies on gp130 (together with OSMR or LIFR) for signal transduction. Collectively, these data suggested that ERK2 downregulation had a negative effect on a critical signalling component upstream of phosphorylation/activation of STAT3 and STAT1. We hypothesised that such a component was likely to be gp130 or the JAKs. Expression levels of JAK1, JAK2 and TYK2, all engaged upon IL-6-type cytokine signalling, remained unaltered after silencing ERK1 or ERK2 (data not shown). We, therefore, investigated the expression of gp130, which is the most upstream signalling component of all IL-6-type cytokine receptor complexes.
Downregulation of ERK2 leads to the absence of gp130, the essential signal-transducing component of IL-6-type cytokine receptor complexes, independently of MAPK activity U2OS cells were transfected as previously described, stained with an anti-gp130 antibody and analysed by flow cytometry (Figure 3a) . The quantitative expression of gp130 and corresponding statistical significance is shown in Figure 3b , using data from three independent experiments. Strikingly, silencing ERK2 had a major impact on gp130 protein expression on the cells' surface (B80% reduction versus siNS-transfected cells). As this is the molecule to which STAT1 and STAT3 dock in order to become phosphorylated by the JAKs, it explained why these molecules were not phosphorylated by IL-6 and OSM stimulation when ERK2 was silenced (Figure 1b) , and why transcription of OSM target genes was only marginally induced ( Figure 2 ). There was a very small decrease in the levels of gp130 protein upon siERK1 (B5%), but this was not statistically significant and, naturally, there was a massive reduction (B95%) when gp130 was targeted by RNAi.
qPCR was used to measure the mRNA levels of gp130 following silencing of ERK1 or ERK2 (Figure 3c ). The mRNA levels reflected protein expression data shown in Figures 3a and b. Silencing ERK2 decreased the mRNA levels of gp130 down to B35% of the amount of gp130 in siNS-transfected cells, indicating that, somehow, ERK2 controlled the transcription of the GP130 gene. Interestingly, despite the fact that silencing ERK1 was without effect on the activation of STAT3 and STAT1, gp130 mRNA levels were B12.5% lower than those measured in untransfected cells (data not shown) or cells transfected with siNS, and this reduction was statistically significant (Figure 3c ). Regardless, the reduction of gp130 mRNA and protein elicited by siERK1 was not sufficient to have an impact on the phosphorylation of STAT1 and STAT3 (Figure 1b) , nor did it appear to have a negative impact on signalling downstream OSM ( Figure 2 ). Analyses of gp130 phosphorylation per se suggested that the gp130 receptor could not be phosphorylated upon transfection with siERK2 but was still phosphorylated when ERK1 was downregulated (data not shown), further suggesting a specific role for ERK2 in the regulation of gp130.
ERKs phosphorylate many transcription factors, thus promoting transcription of many different genes. RNAi permitted efficient manipulation of protein levels and enzymatic activity of ERK2 concomitantly. For this reason, and in order to establish if it was the lack of enzymatic activity of ERK2 that affected the expression of gp130, U2OS cells were treated with different well-established MAPK kinase (MEK) inhibitors and gp130 expression assessed (Figures 3d-f) . In order to activate ERK1/2 and test the efficacy of the inhibitors, cells were incubated with fetal calf serum (FCS) for 15 min only. Regardless of the incubation time or dose, and despite being functional as judged by the inhibition of ERK1/2 phosphorylation, PD0325901, PD98059 and U0126 did not influence the total amount of gp130 (Figure 3d ) or the cell surface localisation of the protein as determined by a highly quantitative flow cytometry-based method (Figure 3e ). These inhibitors block both the phosphorylation and subsequent translocation of ERK1/2 into the nucleus. They do not affect ERK1/2 auto-phosphorylation or phosphorylation independent of MEKs. We therefore also used FR180204, an ERK1/2 ATPcompetitive inhibitor. Cells were incubated with this inhibitor and stimulated with FCS. This inhibitor did not affect phosphorylation of ERK1/2 per se, but it blocked the phosphorylation of an ERK1/2 downstream target, RSK1, used here as a readout for inhibitor efficacy (Figure 3f ). Despite the clear inhibition of RSK1 phosphorylation, no alteration in gp130 expression was detected at any time-point. These data suggested that ERK2 might provide a structural role in the regulation of gp130, which is independent of enzymatic activity. This was intriguing, as the knockdown of ERK2 affected gp130 mRNA levels, implying a role in its transcriptional regulation (Figure 3c ). ERK2 binds to the promoter of GP130 and regulates GP130 transcription Having shown that the enzymatic activity of ERK2 was not critical for full expression of gp130 but that downregulation of ERK2 protein affected both its protein expression and mRNA induction, we next asked whether ERK2 acted at the level of the GP130 promoter. For that purpose, chromatin immunoprecipitation (ChIP) experiments were done using an anti-ERK2 antibody and primer pairs that hybridised to different locations of the GP130 gene (Figure 4a and Supplementary Table SIII) . As additional controls, a non-related region of chromosome 5 was also amplified and RNA polymerase II was also immunoprecipitated. In all experiments immunoprecipitations using IgG were carried out in order to calculate background binding. ERK2 and RNA polymerase II were shown to bind to the GP130 promoter using three distinct primer pairs (Supplementary Table SIII) . Neither ERK2 nor RNA polymerase II significantly bound outside the promoter or to another chromatin region in chromosome 5 (Figures 4b and c) . This suggested that ERK2 could facilitate the transcription of the constitutively active gene GP130, most likely by virtue of interacting with the transcriptional machinery.
We also analysed transcriptional regulation of gp130 using reporter assays. More specifically, we performed GP130 promoter luciferase assays and showed that gp130 transcription is highly impaired in cells that had ERK2 silenced ( Figure 5) , thus corroborating the ChIP data shown in Figure 4 . In addition, the GP130 promoter has a number of g-interferon activated transcriptional element (GATE) sequences, including one À 157 to À 153 upstream of the TSS, and ERK2 is known to be capable of binding to these sequences (Supplementary Figure S2) . In order to establish if ERK2 regulated gp130 expression by directly binding to this particular GATE, we modified the original wild-type GP130 reporter construct by site-directed mutagenesis (CAAAG4CACAG) but the mutation did not have an impact on the expression of gp130 ( Figure 5 ). In addition, experiments using the transcription inhibitor actinomycin D to block on-going transcription demonstrated that the presence of ERK2 had an impact on the stability of gp130 mRNA. Indeed, in cells that were transfected with siERK2, gp130 mRNA had a half-life of 3 h as opposed to 12.5 h, which was measured for cells transfected with the siNS (Figure 6 ).
The impact that siERK2 has on gp130 mRNA and protein is a specific effect observed on several types of cancer cells Importantly, the inhibition of gp130 upon ERK2 silencing was not particular to U2OS cells. It was observed in additional cancer cell lines of different origins, with different known mutations (Supplementary Table SIV) (Figure 7a ). A549 (lung), MCF-7 (breast), HeLa (cervix), DU145 and LNCaP C4-2 (both prostate) were transfected as described previously, and samples divided into two experimental groups: one group was analysed by flow cytometry for gp130 cell surface expression and another was analysed by western blotting for ERK1/ERK2 levels. In every cell type analysed, a reduction in ERK2 expression led to a decrease in the amounts of gp130 on the cells' surface. While most cells have more ERK2 than ERK1, MCF-7 expresses comparable levels of these proteins (Figure 7a ). This argues against the siERK2 phenotype being purely due to quantitative differences between ERK1 and ERK2 expression. The data thus far further suggest that ERK1 and ERK2 have important non-redundant, non-overlapping functions, including the regulation of gp130 expression, a key component of IL-6-type cytokine signalling. Table SIII) . Data are representative of three independent experiments each using duplicate samples that yielded identical results. Statistical analysis was carried out using Student's t-test (*Po0.05, **Po0.01, ***Po0.005 versus siNS-transfected control). Figure 5 . GP130 is transcriptionally regulated by ERK2. RNAi was initiated 24 h prior to co-transfection of U2OS cells with gp130 promoter-Firefly luciferase constructs that were either wild-type or mutant at the GATE, with a CMV promoter/Renilla-luciferase plasmid construct. Twenty four hours later, both Firefly-and Renilla-luciferase activities were quantified. For data analysis, the obtained luminescence for the Firefly luciferase activity was normalised to the luminescence obtained for the Renilla luciferase activity. The experiments were done three times and yielded identical results, and the data represent the means of luciferase activity ± s.e.m. Statistical analysis was carried out using Student's t-test (*Po0.05, **Po0.01, ***Po0.005 versus wild-type siNS-transfected control). . ERK2 contributes to the stability of gp130 mRNA. RNAi was induced as before and 48 h later cells were incubated with the transcription inhibitor, actinomycin D (5 mg/ml) for varying periods of time as indicated in the figure. RNA was extracted and analysed by qPCR as before. The data are presented as the mean gp130 mRNA ± s.e.m. and, for each sample, the initial amount of gp130 was considered to represent 100%. The experiments were done three times and yielded identical results. Statistical analysis was carried out using Student's t-test (*Po0.05, **Po0.01, ***Po0.005 versus siNS-transfected cells).
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The amount of ERK2 protein in cells correlates with the expression of gp130
Eight different cell lines were analysed for the endogenous expression of ERK2 and gp130 (Figure 7b ). Despite the highly disparate cellular backgrounds and growth properties of these cells, 75% of the cell lines analysed (6/8) showed striking correlation between ERK2 and gp130 expression (r 2 ¼ 0.73). The two outliers were A549 and HeLa cells. Conversely, if ERK2 directly regulated the expression of gp130, then it would be expected that modulating the intracellular concentration of ERK2 would have a direct impact on gp130 expression levels (Figure 7c ). For that purpose, U2OS cells were transfected with different amounts of siERK2, stained dually with anti-ERK2 and anti-gp130, and analysed by flow cytometry (Figure 7c ). Untransfected cells and cells transfected with non-targeting siRNA were used as controls and behaved essentially in an identical manner. The higher the ERK2 knockdown, the greater the reduction in gp130 levels. Taken together, the data are consistent with ERK2 being critical for the control of gp130 expression and, importantly, with the fact that this effect is not cell type-specific and is independent of cellular background.
DISCUSSION
Using RNAi we have successfully genetically manipulated ERK1 and ERK2 independently (Figure 1b) . This has unravelled undescribed distinct, non-overlapping, roles for these two isoforms. Indeed, ERK2 downregulation leads to a highly significant decrease in gp130 protein expression, whereas silencing ERK1 has no effect (Figures 3a and b) . Knockdowns obtained using siRNA or transgene expression by transient transfections are seldom achieved with 100% efficiency, and it remains a possibility that if ERK2 was totally absent from the cells, a full inhibition of gp130 expression would have been achieved. Downregulation of ERK1 leads to a small decrease in the levels of gp130 mRNA but siERK2 causes a major reduction, suggesting that ERK2 may regulate gp130 transcriptionally (Figure 3c ). If this was the case and ERK2 worked in the 'classical manner', then one would expect the kinase activity to be required. Yet, this does not seem to be the case, as inhibition of phosphorylation/activation of ERK1/ERK2 with specific chemical inhibitors has no impact on gp130 expression (Figures 3d-f) . Instead, ERK2 likely regulates gp130 expression by binding to the GP130 promoter (Figure 4) . ERK2 may interact with other transcription factors, co-activators or alter the chromatin structure, thereby facilitating the transcription of GP130. Our data suggest that ERK2 is more likely to interact with the transcriptional machinery than causing chromatin remodelling.
Importantly, ERK2 regulates the expression of gp130 in many cancer cell types, characterised by different mutations and cellular backgrounds (Supplementary Table SIV strongly suggests that ERK2 can directly modulate the expression of gp130. Indeed, a reduction in gp130 expression can be easily achieved by transfecting cells with increased amounts of siERK2 (Figure 7c ). This suggests that there is a straight correlation between the amount of ERK2 and gp130 that cells express. Clearly, ERK2 is not the sole determinant of gp130 protein synthesis, as A549 and HeLa cells deviated from all other cell lines analysed, thus far for reasons that are yet to be understood.
The absence of gp130 upon RNAi against ERK2 explained why STAT1 and STAT3 could not be phosphorylated upon IL-6 or OSM treatment (Figures 1a and b) , as gp130 is required for the activation of the JAKs, which are, in turn, responsible for phosphorylating STAT docking sites on the receptor. It also explains why the mRNA induction of an immediate-early-STAT3 gene such as SOCS3 was so severely impaired when the levels of ERK2 were reduced (Figure 2a) , as was the induction of EGR-1, a STAT3/ERK target (Figure 2b) , and the expression of STAT3 itself (Figures 1b and c) . Intriguingly, silencing ERK1 led to a statistically significant increase in the relative induction of SOCS3 and EGR-1 mRNA after OSM treatment (Figure 2 ). This suggests that ERK1 and ERK2 have opposite roles in the induction of particular sets of genes and that ERK2 can perhaps negatively regulate ERK1. In fact, silencing ERK2 led to an increase in ERK1 phosphorylation, which was seen regardless of cytokine treatment (Figure 1b and Supplementary Figure S1 ), further supporting this hypothesis.
ERK1 and ERK2 are generally described as homologous molecules with parallel activities, kinetics and substrates. 33 The proteins are 44 and 42 kDa, respectively, and share B85% sequence homology. 34 These kinases are phosphorylated on threonine and tyrosine residues and are spatio-temporally regulated. 34, 35 Their differing biological roles have been attributed mostly to the higher expression level of ERK2 compared with ERK1. 27 The fact that these proteins have structural differences, however, raises the possibility that they may have different functions as well. 36 There is, in fact, an evergrowing body of evidence suggesting that this is indeed the case. For example, ERK1 and ERK2 are thought to have different roles in Ras-mediated transformation, 37 in proliferation, 38 in epithelial-tomesenchymal transformation 39 and in cell migration during the embryonic development. 40 Interestingly, ERK1 has an additional domain that has recently been suggested to slow down its nuclear import when compared with ERK2, which may lead to different biological responses.
41
ERK1/2 also have a multitude of biologically important nonenzymatic roles. 31 Particularly relevant to this work is the realisation that ERK2 can act as a transcriptional regulator and in chromatin remodelling by associating with the DNA, 42 or by directly binding to proteins such as poly[ADP-ribose]-polymerase (PARP)-1 43 and topoisomerase II. 44 Although the latter does not require ERK enzymatic activity, it does require ERK to be phosphorylated. 43, 44 The regulation of gp130 by ERK2 thus appears to be unique in the sense that neither phosphorylation of ERK2 by MEKs nor its kinase activity is essential for the expression of gp130. In addition, the association of ERK2 with the GP130 promoter can be seen in 'resting' cells, in the absence of OSM. ERK2 was shown to repress interferon-stimulated genes (ISGs) by binding to a DNA consensus sequence embedded in GATEs independently of kinase activity, and such sequences were shown to be located B90 bp upstream the TSS. 42 However, other researchers have provided evidence that the activity of MEKK1/ ERK was required for the transcription of a subset of g-ISGs by C/EBP-b via these elements. 45 Irrespective, the GP130 promoter has several GATEs and one such ERK-binding sequence (G/CAAAG/C), which is 157 bp upstream from the TSS (Supplementary Figure S2) , is located equidistantly from two CAT boxes and two SP1 consensus sequences, downstream of a SBE and an APRE sequences. We initially hypothesised that ERK2 bound to this putative ERK binding sequence and promoted, directly or indirectly, the transcription of GP130, which is a STAT3-target gene.
14, 46 We have, however, mutated this sequence ( Figure 5 ) and also the other more upstream GATEs (data not shown), and shown that gp130 expression is similar in siNS-and siERK2-transfected cells, thus ruling out the hypothesis that ERK2 is acting in a transcription factor-like fashion upon the GP130 promoter via GATEs. STAT binding sites are often located in close proximity to those of other transcription factors, and it is thus possible that ERK2 influences, somehow, the interactions between STAT3, SP-1, AP-1, NF-kB and/or C/EBP-b. STAT3 and ERK2 have certainly been shown to interact in the cytoplasm 47 and it is thus possible that they may also do so on the chromatin. The increasing realisation that kinases can associate both with the regulatory regions and with the entire transcribed region of target genes 48 strongly suggests that they have more prominent roles at the chromatin level than initially envisaged. We are therefore scrutinising, among other possibilities, if ERK2 regulates the expression of gp130 by recruiting RNA polymerase II, by changing histone methylation patterns, or by directly interacting with transcription activators, co-activators or other transcription factors on the promoter. Interestingly, gp130 mRNA in cells with silenced ERK2 is much less stable than that in untransfected cells, or cells transfected with a non-targeting siRNA or siERK1 ( Figure 6 ).
The common cytokine receptor subunit, gp130, is pivotal for controlling the action of all cytokines that belong to the IL-6 superfamily.
14 These cytokines display some redundancy and they are mainly involved in various cellular processes such as the acute phase response, inflammation, immune responses and cell survival. Unsurprisingly, gp130
À / À mice die at birth, or shortly after, and most knockout studies have had to resort to conditional mice mutants (reviewed in Fasnacht et al. 49 ) Such studies confirmed that gp130 has vital pleiotropic roles in many types of cells and its role in cancer cannot be understated.
Overall, our results identify a new function for ERK2 that is not shared by ERK1. As MAPKs are critical mitogenic kinases that participate in many tumorigenic pathways, and as IL-6-type cytokines are critically involved in inflammatory and oncogenic processes, the regulation of gp130 expression by ERK2 likely contributes to cancer cell survival and cancer progression. Indeed, it has recently been shown that pro-inflammatory cytokines such as IL-1 or tumour necrosis factor (TNF) dampen excessive IL-6-mediated signalling by accelerating gp130 internalisation and degradation. This mechanism is thus thought to prevent overshooting inflammation promoting activities of IL-6. 50 Furthermore, it has recently been shown that ERK2 can be cleaved through p53-dependent activation of caspases in a process that can affect both its kinase activity and the protein amount. 51 As many cancer cells have lost p53 expression, this might explain the enhanced gp130 expression often seen in cancer cells. Taken together, our study highlights an important novel regulatory mechanism of gp130 expression, thereby opening up the possibility of additional targeting strategies in the clinic.
MATERIALS AND METHODS
Cell culture
Cells were grown in DMEM supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 50 units/ml penicillin and 50 mg/ml streptomycin in a humidified atmosphere of 10% CO 2 at 37 1C. Prostate cancer cells were cultured in RPMI medium in 5% CO 2 . Cytokines and drugs IL-6, sIL-6R, OSM (Peprotech, London, UK); LIF (R&D, Minneapolis, MN, USA); PD0325901 (Pfizer, Dorset, UK); PD98059, U0126, FR180204 (Calbiochem, Nottingham, UK); Actinomycin D (Sigma-Aldrich, Dorset, UK). siRNA oligonucleotides were from Dharmacon (Lafayette, CO, USA) and were transfected using Lipofectamine RNAiMax.
RNA interference (RNAi)
This was done essentially as previously described, 52 using Lipofectamine RNAiMAX (Invitrogen, Paisley, UK) according to the manufacturer's instructions.
Protein analysis
Receptors were isolated using a lysis buffer containing: 93.2 mM di-sodium hydrogen phosphate, 6.8 mM sodium di-hydrogen phosphate, 0.5% (v/v) Triton X-100, 0.5 mM EDTA pH8, 1 mM sodium orthovanadate, 100 U/ml aprotinin, 10 mg/ml leupeptin and 1 mM phenylmethylsulphonyl fluoride. Unless gp130 was being analysed at the same time, STATs and ERKs were isolated using Schindler's buffer. 52 Western blots were stripped with 2 M glycine, pH 2.5/0.5% SDS (shaking overnight, room temperature), washed with water, equilibrated with TBST and incubated with subsequent antibodies.
Flow cytometry
Cells were incubated with anti-gp130-PE and/or ERK2-APC for 1 h at 4 1C, washed five times with cold PBS and fixed with 1% (w/v) p-formaldehyde. For indirect staining, cells were incubated first with anti-gp130 (B-R3) or isotype control followed by anti-mouse-PE each for 30 min at 4 1C. Cells were analysed using a FACS Canto or FACS Calibur (BD Biosciences, San Jose, CA, USA) and data mining was done with FlowJo (Tree Star, Inc, Ashland, OR, USA). Geometric means were used for the analyses.
Real-time PCR
Gene expression analysis was done by quantitative two-step reverse transcription PCR. Reverse transcription was performed using total RNA and the Transcriptor First Strand cDNA Synthesis kit (Roche). A combination of anchored-oligo(dT) 18 and random hexamer priming was used to increase sensitivity of the reaction. qPCR was done using the FastStart Universal SYBR Green Master (Rox) with specific primer pairs designed using the Universal ProbeLibrary Software (Roche) (Supplementary Table SII) . For each target mRNA analysed, 5 ml of FastStart Universal SYBR Green master mix, 400 nM of each primer pair, 2.2 ml deionised water and 2 ml of cDNA were mixed in 384-well plates in duplicates using a robot, and qPCR carried out on an ABI PRISM 7900HT 
Chromatin immunoprecipitation
This was done as described by Nelson et al., using protein G Dynabeads blocked overnight with 3% (w/v) bovine serum albumin (BSA) diluted in immunoprecipitation buffer without inhibitors (50 mM Tris-HCl, pH 7.5; 0.5% (v/v) NP-40; 1% (v/v) Triton X-100; 150 mM NaCl; 5 mM EDTA; 2 mg/ml salmon sperm DNA; 0.1% (w/v) sodium azide). ChIP was done using 150 mg of chromatin and 10 mg of anti-ERK2, or 2 mg of anti-RNA polymerase II. Mouse and rabbit IgGs were also used as controls. Primer sequences used are shown in Supplementary Table SIII. DNA quantification (samples and input) was done using a standard curve made from the input. Samples were normalised to their corresponding input and presented as a percentage of input.
Luciferase assays
Cells were transfected with siRNA oligonucleotides as described above. Twenty-four hours later, cells were co-transfected with 100 ng of full-length gp130 promoter (p2433)/Firefly-luciferase and 10 ng of CMV promoter/ Renilla-luciferase plasmid constructs using attractene transfection reagent (Qiagen). The day after, both Firefly-and Renilla-luciferase activities were quantified using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. Luminescence was detected using a PHERAstar Plus plate reader. The measured luminescence for Firefly luciferase activity was normalised to that of Renilla luciferase. mRNA stability Cells were transfected with siRNA oligonucleotides as before. Forty-eight hours after transfection, cells were treated with 5 mg/ml Actinomycin D for 0, 0.5, 1, 2 or 3 h. Subsequently, RNA was isolated using an RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. Gene expression analysis was performed by qPCR as described before, using b-actin and GAPDH as housekeeping genes.
Statistical analysis
Mean±standard error (s.e.m.) of three independent experiments was calculated. Student's t-test was used to determine the statistical significance of the differences observed between conditions. A two-tailed P-value below 0.05 was considered significant. *Po0.05, **Po0.01, ***Po0.005.
